首页/数据集/Transcription profiling of whole blood samples from humans with Immune Thrombocytopenic Purpura (ITP) and control patients

Transcription profiling of whole blood samples from humans with Immune Thrombocytopenic Purpura (ITP) and control patients

ChEBI2006-09-18 更新2026-07-21 收录

自身免疫疾病基因

血液转录组

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-SMDB-3822 数据链接链接失效反馈

官方服务：

资源简介：

Transcription profiling of whole blood samples from humans with Immune Thrombocytopenic Purpura (ITP) and control patients

应用场景：

创建时间：

2006-09-18

相关数据集

ParityImmune

生殖健康流行病学

血液转录组

Blood transcriptome from women participating in the Norwegian Women and Cancer study (NOWAC)EGA dataset EGAD00010001412

NIAID Data Ecosystem90

Gene expression analysis of cancer-related fatigue in whole blood from breast cancer survivors

癌症幸存者症状机制

血液转录组

Cancer-related fatigue is one of the most frequent complaints among breast cancer survivors, with a major negative impact on general life. However, the etiology behind this syndrome is still unraveled

NIAID Data Ecosystem70

Deciphering the genetic regulation of peripheral blood transcriptome in pigs through allele-specific expression analysis and expression genome-wide association study

遗传调控

血液转录组

Efforts to improve resilience in livestock production systems have focused on two objectives: investigating the genetic control of immune function as it pertains to robustness and disease resistance,

NIAID Data Ecosystem60

Blood transcriptomes of chronic HCV patients four years after therapy-induced viral clearance. Homo sapiens

HCV丙型肝炎病毒

血液转录组

Little is known on the immune status in liver and blood of chronic HCV patients long after therapy-induced viral clearance. In this study, we demonstrate that 4 years after clearance, regulation of HC

NIAID Data Ecosystem70

Transcriptomics data of blood and brain from the YAC128 Huntington's disease mouse model [blood]. Transcriptomics data of blood and brain from the YAC128 Huntington's disease mouse model [blood]

亨廷顿病生物标志物

血液转录组

Therapeutic development for Huntington's disease (HD) would benefit from a method to monitor disease progression and treatment efficacy, ideally using blood biomarkers. Previously, HD-specific signatu

NIAID Data Ecosystem70